Cilostazol Catalog No.:M9487-2 K562 cells) treatment inhibits MAPK/ERK/JNK

K562 cells) treatment inhibits MAPK/ERK/JNK downstream signaling and diminishes Jak2/Stat3/Akt expression

PubMed PMID: 25649658

In vivo it shows pronounced and robust anti-tumor activity in both A549 NSCLC xenograft and RKO27 colon carcinoma model

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Molecular Weight: 170

Cilostazol Catalog No.:M9487-2 K562 cells) treatment inhibits MAPK/ERK/JNKCilostazol is a quinolinone derivative medication used in the alleviation of the symptom of claudication in individuals with peripheral vascular disease. Cilostazol is a phosphodiesterase inhibitor with therapeutic focus on cyclic adenosine monophosphate (cAMP). It inhibits platelet aggregation and is a direct arterial vasodilator. Its main effects are dilation of the arteries supplying blood to the legs and decreasing platelet coagulation. It is